We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A drug dubbed CX717, made by Cortex Pharmaceuticals, reverses the biological and behavioral effects of sleep deprivation, according to newly published results of animal studies.
The FDA has granted tentative approval to Caraco Pharmaceutical Laboratories
for an abbreviated new drug application for Zolpidem Tartrate in 5- and 10-mg
dosage strengths.
Lorus Therapeutics announced the continued success in the development of its
small molecule anticancer program with the selection of a sub-class of lead
molecules from its small molecule program.
According to three studies published in the Journal of Clinical Oncology,
treatment with the investigational drug temsirolimus, a cell signal blocker,
may be effective against several types of cancer.
Immunotope has submitted an investigational new drug application (IND) to the
FDA in collaboration with Duke University to initiate a Phase I ovarian cancer
clinical trial.
Allon Therapeutics has commenced dosing the first patient in a Phase I clinical
trial to evaluate the AL-208 as an intravenous treatment for mild cognitive
impairment associated with postcoronary artery bypass graft surgery.